- Home
- CHMI vs EPRX Comparison
CHMI vs EPRX Comparison
Compare CHMI & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHMI
- EPRX
- Stock Information
- Founded
- CHMI 2012
- EPRX 2011
- Country
- CHMI United States
- EPRX Canada
- Employees
- CHMI N/A
- EPRX N/A
- Industry
- CHMI Real Estate Investment Trusts
- EPRX
- Sector
- CHMI Real Estate
- EPRX
- Exchange
- CHMI Nasdaq
- EPRX NYSE
- Market Cap
- CHMI 92.0M
- EPRX 109.7M
- IPO Year
- CHMI 2013
- EPRX N/A
- Fundamental
- Price
- CHMI $3.32
- EPRX $3.07
- Analyst Decision
- CHMI Buy
- EPRX Strong Buy
- Analyst Count
- CHMI 3
- EPRX 1
- Target Price
- CHMI $5.00
- EPRX $9.00
- AVG Volume (30 Days)
- CHMI 315.5K
- EPRX 5.7K
- Earning Date
- CHMI 03-06-2025
- EPRX 02-11-2025
- Dividend Yield
- CHMI 18.05%
- EPRX N/A
- EPS Growth
- CHMI N/A
- EPRX N/A
- EPS
- CHMI N/A
- EPRX N/A
- Revenue
- CHMI N/A
- EPRX N/A
- Revenue This Year
- CHMI N/A
- EPRX N/A
- Revenue Next Year
- CHMI $27.78
- EPRX N/A
- P/E Ratio
- CHMI N/A
- EPRX N/A
- Revenue Growth
- CHMI N/A
- EPRX N/A
- 52 Week Low
- CHMI $2.50
- EPRX $2.20
- 52 Week High
- CHMI $3.99
- EPRX $4.08
- Technical
- Relative Strength Index (RSI)
- CHMI 73.18
- EPRX N/A
- Support Level
- CHMI $3.07
- EPRX N/A
- Resistance Level
- CHMI $3.33
- EPRX N/A
- Average True Range (ATR)
- CHMI 0.09
- EPRX 0.00
- MACD
- CHMI 0.04
- EPRX 0.00
- Stochastic Oscillator
- CHMI 91.67
- EPRX 0.00
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.